

# Care of Cancer Survivors

M. Alma Rodriguez, MD, MACP Professor, Department of Lymphoma-Myeloma Medical Director, Survivorship Programs, M.D. Anderson Cancer Center

October 6, 2022



### Objectives

- 1. Review the history of the development of the concept of Cancer Survivorship
- 2. Identify the components of Survivorship Care
- 3. Discuss the characteristics of the population of Cancer Survivors in the United States
- 4. Identify the late effects and risks for second malignancies in Cancer Survivors
- 5. Discuss strategies to address the Survivorship Care health domains, and identify barriers

#### Disclosure of Conflicts of Interest

• M. Alma Rodriguez, MD, MACP, has no relevant financial relationships to disclose.

#### A Brief Guide to the History of Cancer Survivorship



#### 1971:

President Nixon signs "National Cancer Act"

How the National Cancer Act has changed the graphics of survival for cancer patients

#### A Brief Guide to the History of Cancer Survivorship



#### 1971:

President Nixon signs "National Cancer Act"

1985:

Seasons of Survival F. Mullan, NEJM, 1985, 313:270-273

How the National Cancer Act has changed the graphics of survival for cancer patients The stages of the cancer journey are unique and have different health care needs



### \*Phases of Cancer Survivorship: From *Cancer Remission* to *Recovery* and *Wellness*







- <u>Acute</u>: Begins with diagnosis of cancer, and includes the period of *testing and treatment* of cancer
- <u>Extended</u> (Intermediate): Begins upon reaching remission and concluding the acute treatment; this phase can include *maintenance*, *consolidation*, *or watchful monitoring*
- <u>Permanent</u> (Long-Term): Depending on disease type, this is the phase of *low risk of recurrence*, equated with 'cure' in many cases
- \*Fitzhugh Mullan. Seasons of Survival: Reflections by a Physician with Cancer. NEJM 1985;313(4):270-3

NOTE: new category of long-term survivors are *patients who live with chronic malignancies*, such as chronic leukemia

#### A Brief Guide to the History of Cancer Survivorship



#### 1971:

President Nixon signs "National Cancer Act"



#### 1985:

Seasons of Survival F. Mullan, NEJM, 1985, 313:270-273



#### 1996:

Office of Cancer Survivorship Established by NCI

How the National Cancer Act has changed the graphics of survival for cancer patients The stages of the cancer journey are unique and have different health care needs

Defining a "Survivor" – it depends on the stage of the journey



#### Who is a Cancer Survivor?



An individual is considered a cancer survivor <u>from the time of</u> <u>diagnosis</u>, <u>through the balance of his or her life</u>. Family <u>members</u>, <u>friends</u>, <u>and caregivers</u> are also impacted by the survivorship experience, and therefore included in this definition.

NCI Office of Cancer Survivorship, 1996

#### A Brief Guide to the History of Cancer Survivorship

1971:

President Nixon signs "National Cancer Act"

How the National Cancer Act has changed the graphics of survival for cancer patients V

1985:


Seasons of Survival F. Mullan, NEJM, 1985, 313:270-273

The stages of the cancer journey are unique and have different health care needs



1996:

Office of Cancer
Survivorship Established
by NCI






2006:

From Cancer Patient to Cancer Survivor: Lost in Transition

The domains of care necessary in any care model that is designed to address Survivorship Care needs



#### Survivorship Healthcare Challenges: Lost in Transition



2006, National Academies Press; IOM, Wash. D.C.

- Persistent symptoms after cancer treatment
- Health effects new onset years after treatment
- Emotional symptoms, loss of relationships, economic distress
- Difficulty finding physicians after cancer treatment
- Lack of communication among physicians

#### **Key Domains of Survivorship Care**

#### **Cancer Surveillance and Screening**

Detection and treatment of late malignancy

#### **Risk Reduction and Cancer Prevention**

• Lifestyle changes to prevent cancer and risk

#### Late Effects / Side Effects Management

• Health maintenance and preservation of vital organ

#### **Psychosocial Functioning**

 Psychosocial support services to maintain healthy relationships and restored life

# A Brief Guide to the History of Cancer Survivorship

1971:
President Nixon signs
"National Cancer Act"

1985:
Seasons of Survival
F. Mullan, NEJM, 1985,
313:270-273

1996:
Office of Cancer
Survivorship Established
by NCI

2006:
From Cancer Patient to
Cancer Survivor: Lost in
Transition

2013:
Delivering High-Quality
Cancer Care: Charting a
New Course for a System in
Crisis


How the National Cancer Act has changed the graphics of survival for cancer patients The stages of the cancer journey are unique and have different health care needs

Defining a "Survivor" – it depends on the stage of the journey


The domains of care necessary in any care model that is designed to address Survivorship Care needs

Outline the Components of Cancer Care Cycle


### The Cancer Care Cycle




#### 18 Million Cancer Survivors in 2022




### Not All Survivors Are The Same....



#### Cancer Prevalence and Projections in U.S. Population from 1975–2040



REFERENCE: Bluethmann SM, Mariotto AB, Rowland, JH. Anticipating the "Silver Tsunami": Prevalence Trajectories and Comorbidity Burden among Older Cancer Survivors in the United States, Cancer Epidemiol Biomarkers Prev. 2016;25:1029-1036.




REFERENCE: American Cancer Society. Cancer Treatment & Survivorship Facts & Figures 2016-2017. Atlanta: American Cancer Society; 2016.

Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R. and Jemal, A. (2016), Cancer treatment and survivorship statistics, 2016. CA: A Cancer Journal for Clinicians.

## Declining Mortality Across Multiple Cancers: 2020 National Report

#### NATIONAL TRENDS IN CANCER DEATH RATES



AVERAGE ANNUAL PERCENT CHANGE (AAPC) 2013-2017

\*AAPC is significantly different from zero (p < .05).

Seer.cancer.gov
Source: Annual Report to the Nation

Most significant trends in declining death rates are in Lung & Bronchus and Melanoma thanks to check-point inhibitor immune modulating agents: Nivolumab, Pembrolizumab and Ipilimumab



### Not All Survivors Are The Same....

- 1. Risk of recurrence depends on the primary malignancy type and stage at diagnosis.
- 2. Risk of secondary late effects of treatment, including subsequent cancers, depend on the type of treatment, combinations of treatment, as well as the age and health of the patient.
- 3. Survivorship care plans therefore must be tailored to <u>each person's</u> <u>tumor, treatment, and health history.</u>



### Complications of cancer therapy

- Anatomic or functional changes secondary to surgery and/or radiation
- Organ toxicity secondary to systemic chemotherapies that lead to premature onset of chronic illnesses
- Immune deficits or autoimmune syndromes secondary to immune system targeted therapies
- Psychological disturbances
- Socioeconomic burdens
- Increased risk of second malignancies
- In addition, other health co-morbidities can worsen, particularly in older cancer patients




### Risk factors for second malignancies

- Treatment related
  - Radiation, chemotherapy, hormonal
- Hereditary
  - Genetic or familial syndromes
- Environmental
  - Exposure to harmful conditions
- Type of primary cancer
  - Some cancers have risk of other second primary cancers
- Lifestyle
  - Obesity
  - Tobacco use: smoking, chewing
  - Alcohol consumption
- Health related
  - Infectious illnesses
  - Autoimmune disorders



### Psychological and Socioeconomic Effects

- Anxiety or fear of relapse
- Depression
- Grief over loss of health, lifestyle, relationships, work
- Body image
- Sexuality concerns
- Employment challenges
- Economic losses





#### **Returning to Life Activities**



- Gradual integration to normal prior level of activity recommended
- Fatigue is a common complaint can be improved by exercise
- Special activity considerations for people who have lymphedema, ostomy bags, and lung or limb resections: recommend consult with PM&R
- Impaired immunity post cellular therapies is a concern for travel outside the USA; immunization and precautions per CDC guidelines



### **Fertility**

- Strategies to preserve fertility prior to treatment should have been discussed
- Counseling regarding risk of infertility and possible fetal genetic risks related to specific treatments also pretreatment
- Post treatment evaluation for fertility:
  - Sperm counts at least 6 months after treatment
  - Return of menses may not always relate to fertility
- Options for in-vitro fertilization, surrogacy or adoption to be discussed with Fertility experts and Family Counselors, if cannot conceive post treatment.





### Survivorship Care Models

### Oncology Clinic

Patient continues care in an Oncology clinic setting

Surveillance for late recurrences and second malignancies

### Survivorship Clinic

Dedicated personnel to survivorship care (APPs, Prevention specialists)

Multidisciplinary care based on IOM domains of care

### Primary Care Transition


Patients return to their PCP

Recommendations for Survivorship care given to the patient and PCP to follow (Survivorship Care Plan)



### MD Anderson Survivorship Model: Tiers of Risk

Rodriguez MA, Zandstra F. *Models of Survivorship Care*. In <u>Advances in Cancer Survivorship Management</u>. Foxhall L, Rodriguez M A, eds. 2015; 7-25. Springer, New York, NY.



### Key Domains of Survivorship Care

MD Anderson Cancer Center

Making Cancer History'

#### Survivorship - Invasive Breast Cancer

Page 1 of 3

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

Note: Mammograms may continue as long as a woman has a 10-year life expectancy and no co-morbidities that would limit the diagnostic evaluation or treatment of any identified problem. DISPOSITION ELIGIBILITY CONCURRENT COMPONENTS See evaluation for OF VISIT recurrence in Breast · History and physical with clinical breast exam annually Suspect Cancer - Invasive new primary or Screening mammogram annually<sup>2</sup> algorithm SURVEILLANCE biopsy-proven · Assess for compliance with hormone therapy and assess for toxicities if recurrence? Continue survivorship monitoring Consider the following: Fatigue assessment Bone health<sup>3</sup> (see Breast Cancer Survivorship: Neuropathy assessment Bone Health algorithm) MONITORING FOR Cognitive dysfunction assessment · Cardiac screening4 Gynecological assessment if on LATE EFFECTS · Patient education regarding symptoms, including tamoxifen radiation therapy complications, if appropriate Female or male Lymphedema assessment Sexual health/fertility with invasive breast cancer 5 years Patient education, counseling, and screening: from date of Lifestyle risk assessment\* diagnosis1 Cancer screening<sup>6</sup> and NED Refer or consult RISK REDUCTION/ HPV vaccination as clinically indicated (see HPV Vaccination algorithm) as indicated EARLY DETECTION · Screening for Hepatitis B and C as clinically indicated (see Hepatitis Screening and Management - HBV and HCV algorithm) Genetic screening (if not already done) (see Genetic Counseling algorithm) Vaccinations<sup>7</sup> as appropriate PSYCHOSOCIAL Distress management (see Distress Screening and Psychosocial Management algorithm) FUNCTIONING Financial stressors · Social support · Body image NED - no evidence of disease

- <sup>1</sup>Completion of all treatment with the exception of hormonal agents
- \*Consider tomosynthesis
- <sup>3</sup> All postmenopausal women (especially those on aromatase inhibitors) and premenopausal women on ovarian suppression

Copyright 2019 The University of Texas MD Anderson Cancer Center

Department of Clinical Effectiveness V8

Approved by the Executive Committee of the Medical Stuff on 06/25/2019

**Source:** www.mdanderson.org/education-and-research/resources-for-professionals/clinical-tools-and-resources/practice-algorithms

Cancer Center

Making Cancer History

<sup>&</sup>lt;sup>4</sup>Consider use of Vanderbilt's ABCDE's approach to cardiovascular health

See Physical Activity, Nutrition, and Tobacco Cessation algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice

Includes cervical (if appropriate), colorectal, liver, lung, pancrentic, prostate (if appropriate), and skin cancer screening
Based on Centers for Disease Control and Prevention (CDC) guidelines



### Support tools: Practice Algorithms Available Online

Clinical Tools & Resources > Clinical Practice Algorithms > Cancer Survivorship Algorithms

#### **Clinical Practice Algorithms**

Cancer Survivorship Algorithms

Clinical Management Algorithms

Cancer Screening & Risk Reduction Algorithms

CancerTreatment Algorithms



#### Cancer Survivorship Algorithms

Survivorship algorithms depict best practices for care delivery by providing patient management tools to patients under surveillance for cancer recurrence and secondary cancers. Patients are transitioned to Survivorship once there is no evidence of disease for a specific time period dependent on the patient's cancer site. These algorithms are not intended to replace the independent medical judgment of the physician in the context of individual clinical circumstances to determine a patient's care.

#### **Breast Cancer**

- Bone Health
- Invasive
- Noninvasive

#### Gastrointestinal Cancer

- Anal Cancer
- Colon Cancer
- Esophageal Cancer
- Rectal Cancer

#### Genitourinary Cancer

- Bladder Cancer
- Kidney Cancer
- Penile Cancer

#### Head and Neck Cancer

- <u>Larynx/Hypopharynx Cancer</u>
- <u>Nasopharynx Cancer</u>
- Oral Cavity Cancer
- Oropharynx Cancer
- Salivary Cancer
- Unknown Primary

#### Leukemia

- Acute Lymphoblastic Leukemia (ALL)
- · Acute Myelogenous Leukemia (AML)

#### Lung

- Non-Small Cell Lung Cancer (NSCLC)
- www.mdanderson.org/algorithms



### Support tools: Practice Algorithms App

Clinical Tools & Resources > Clinical Practice Algorithms > Cancer Survivorship Algorithm

This app contains the same up-to-date algorithms developed and used at MD Anderson Cancer Center.

#### **Apple App Store**



#### **Google Play Store**



Technology development and support are provided by Assessment, Intervention and Measurement (AIM) Shared Resource through a Cancer Center Support Grant (CA16672, PI: P. Pisters, MD Anderson Cancer Center), from the National Institutes of Health.

### Survivorship Care Plans: Coordinating Care

#### **Treatment Summary**

- 1. Cancer diagnosis
- 2. Stage of the cancer
- 3. Unique risk characteristics by molecular or tumor marker reports
- 4. Treatments received
- 5. Anticipated potential late effects

#### **Survivorship Care Plan**

- 1. Surveillance exams/tests recommended
- 2. Prevention/screening evaluations based on guidelines
- 3. Monitoring for late effects, as described in treatment summary
- 4. Recommendations for life style changes
- 5. Follow-up plan

#### Survivorship Care Plans: Coordinating Care

#### Treatment Summary and Survivorship Care Plan

- 1. Cancer diagnosis
- Stage and molecular or marker characteristics
- Treatments received.
- 4. Anticipated potential late effects
- ------
- 1. Surveillance exams/tests recommended
- 2. Prevention/screening evaluations based on guidelines
- 3. Monitoring for late effects, as described in treatment summary
- 4. Recommendations for life style changes
- 5. Follow-up plan

<u>www.asco.org/sites/new-</u> <u>www.asco.org/files/content-</u> <u>files/practice-and-quideline</u>

https://www.livestrong.org/we-canhelp/healthy-living-aftertreatment/your-survivorship-care-plan

	tment Summary and Survivorsi General Information		
Patient Name:	Patient DOB:		
Patient phone:	Email:		
	Care Providers (Including Names, I	institution)	
Primary Care Provider:			
Surgeon:			
Radiation Oncologist:			
Medical Oncologist:			
Other Providers:			
	Treatment Summary		
	Diagnosis		
Cancer Type/Location/Histology Subtype:			(agnosis Date (year):
Stage: □I □II □III □Not applicabl	le		
	Treatment		
Surgery □ Yes □No	Surgery Date(s)	(year):	
- 1 1 1 1 1 1 1 1 1 1			
Surgical procedure/location/findings:			
		1- 1-	
	Body area treated:		rte (year):
Systemic Therapy (chemotherapy, hormo	onal therapy, other) $\square$ Yes $\square$ No		
Names of Agents Used			End Dates (year)
		-	
		$\pm$	
Persistent symptoms or side effects at co	mpletion of treatment: :: No :: Ye	s (enter typ	e(s)) :
Persistent symptoms or side effects at co	mpletion of treatment: □ No □ Ye	s (enter typ	e(s)}:
Persistent symptoms or side effects at co	impletion of treatment: $\Box$ No $\Box$ Ye	s (enter typ	e(s)):
Persistent symptoms or side effects at co			e(s)}:
	Familial Cancer Risk Assessme		e(s)) :
Persistent symptoms or side effects at co Genetic/hereditary risk factor(s) or predis	Familial Cancer Risk Assessme		œ(s)) :
Genetic/hereditary risk factor(s) or predi	Familial Cancer Risk Assessme sposing conditions:		e(s)}:
	Familial Cancer Risk Assessme		<b>α</b> (s)}:
Genetic/hereditary risk factor(s) or predi	Familial Cancer Risk Assessme sposing conditions: Genetic testing results:		α(s)):
Genetic/hereditary risk factor(s) or predis Genetic counseling: ::: Yes :::: No	Familial Cancer Risk Assessme spesing conditions: Genetic testing results: Follow-up Care Plan		e(s)}:
Genetic/hereditary risk factor(s) or predis Genetic counseling: ::: Yes :::: No Need for ongoing (adjuvant) treatment fo	Familial Cancer Risk Assessme sposing conditions: Genetic testing results: Follow-up Care Plan or cancer   Yes   No		
Genetic/hereditary risk factor(s) or predi	Familial Cancer Risk Assessme spesing conditions: Genetic testing results: Follow-up Care Plan		e(s)) : Possible Side effects
Genetic/hereditary risk factor(s) or predis Genetic counseling: ::: Yes :::: No Need for ongoing (adjuvant) treatment fo	Familial Cancer Risk Assessme sposing conditions: Genetic testing results: Follow-up Care Plan or cancer   Yes   No		
Genetic/hereditary risk factor(s) or predis Genetic counseling: ::: Yes :::: No Need for ongoing (adjuvant) treatment fo	Familial Cancer Risk Assessme sposing conditions: Genetic testing results: Follow-up Care Plan or cancer   Yes   No		
Genetic/hereditary risk factor(s) or predis Genetic counseling: ::: Yes :::: No Need for ongoing (adjuvant) treatment fo	Familial Cancer Risk Assessme sposing conditions:  Genetic testing results:  Follow-up Care Plan or cancer   Yes   No Planned duration		
Genetic/hereditary risk factor(s) or predis Genetic counseling: □ Yes □ No Need for ongoing (adjuvant) treatment for Additional treatment name	Familial Cancer Risk Assessme sposing conditions:  Genetic testing results:  Follow-up Care Plan or cancer   Yes   No   Planned duration    Schedule of clinical visits	int	Possible Side effects
Genetic/hereditary risk factor(s) or predis Genetic counseling: ::: Yes :::: No Need for ongoing (adjuvant) treatment fo	Familial Cancer Risk Assessme sposing conditions:  Genetic testing results:  Follow-up Care Plan or cancer   Yes   No   Planned duration    Schedule of clinical visits		Possible Side effects
Genetic/hereditary risk factor(s) or predis Genetic counseling: □ Yes □ No Need for ongoing (adjuvant) treatment for Additional treatment name	Familial Cancer Risk Assessme sposing conditions:  Genetic testing results:  Follow-up Care Plan or cancer   Yes   No   Planned duration    Schedule of clinical visits	int	Possible Side effects
Genetic/hereditary risk factor(s) or predis Genetic counseling: □ Yes □ No Need for ongoing (adjuvant) treatment for Additional treatment name	Familial Cancer Risk Assessme sposing conditions:  Genetic testing results:  Follow-up Care Plan or cancer   Yes   No   Planned duration    Schedule of clinical visits	int	Possible Side effects

#### ASCO Survivorship Care Plan

Updated based on consensus conference held on 9.27.13 and the ASCO Survivorship Committee

	r surveillance or o	ther recommended related	
Coordinating Provider		What/When/	Haw Often
Please continue to see your primary age, including cancer screening tests 1. Anything that represents a language of the control of the contr	s. Any symptoms shorand new symptom persistent symptom	ould be brought to the atte n; t	ntion of your provider:
Describing later and lane to one office to	short commence with	Abia town of several and town	
Possible late- and long-term effects	that someone with	this type or cancer and trea	itment may expenence:
Cancer survivors may experience iss			
please speak with your doctors or n			
	☐ Fatigue	☐ Weight changes	☐Stopping smoking
☐ Physical Functioning	☐ Insurance	☐ School/Work	☐Financial advice or
assistance	-		
☐ Memory or concentration loss ☐ Other	☐ Parenting	☐ Fertility	☐ Sexual functioning
Li Other			
A number of lifestyle/behaviors can	affect your ongoin	z health, including the risk fi	or the cancer coming back or
developing another cancer. Discuss			
☐Tobacco use/cessation		□ Diet	
□ Alcohol use		□ Sun screen u	se
□ Weight management (loss/gain)		☐ Physical activ	situ
Coverigin management (reset gam)		E rityacar acus	····y
Resources you may be interested in:			
resources you may be interested in			
Other comments:			
Other comments:			
Other comments: Prepared by:		Delivered on:	

- This Survivorship Care Plan is a cancer treatment summary and follow-up plan is provided to you to keep with your health care records and to share with your primary care provider.
- This summary is a brief record of major aspects of your cancer treatment. You can share your copy with any of your doctors or nurses. However, this is not a detailed or comprehensive record of your care.



### Electronic Health Record Example

	ncer Treatme Provided on 09		
General Information			
Patient name	Our Patient		
Patient ID	2001245		
Date of birth	9/9/1970		
Age	46 y.o.		
Sex	female		
Allergies	Review of patient's a	llergies indicates not on file.	
Provider(s)			
Medical Oncologist	Dr. Smith		
Surgeon	Dr. Jones		
Radiation Oncologist	N/A		
Cancer Diagnosis Stage	Breast cancer Breast cancer Staging form: Breast, AJCC 7th Edition Clinical stage from 9/1/2016: Stage IA (T1, N0, M0) - Unsigned		
Histology	Left: N/A	Right: Invasive Ductal Carcinoma	
Estrogen Receptor	Positive	010000000000000000000000000000000000000	
Progesterone Receptor	Positive		
Her2/neu	Negative		
Hereditary Genetic Findings	BRCA1+ (Hereditary	Breast and Ovarian Cancer syndrome)	
Additional Cancer Diagnosis	No additional cancer	diagnosis	
Background Information			



#### Coordination of Care for Survivors

- Identified challenges:
  - Preparation of the Summary Treatment and Care Plans requires significant amount of time
  - Treatment data may be housed in different record systems or separate treatment facilities
  - Because care is multidisciplinary, responsibility for this document is not clearly explicit
  - The primary care clinician(s) are not identified and updated in the health record by the patient
  - The health records are not visible or transparent across practices



### Survivorship Resources

- NCCN Guidelines for Patients Cancer-related Late and Long-Term Effects
   https://www.nccn.org/patients/guidelines/content/PDF/survivorship-crl-patient.pdf
- NCCN Guidelines for Patients Healthy Living

https://www.nccn.org/patients/guidelines/content/PDF/survivorship-hl-patient.pdf


• National Cancer Institute – Cancer Survivorship:

https://www.cancer.gov/about-cancer/coping/survivorship


- CDC Cancer Survivors: Guidelines to Healthy Living: https://www.cdc.gov/cancer/survivors/
- National Coalition for Cancer Survivorship: <a href="https://canceradvocacy.org/">https://canceradvocacy.org/</a>
- CancerCare: www.Cancercare.org
- American Cancer Society Survivorship: During and After Treatment
   <a href="https://www.cancer.org/treatment/survivorship-during-and-after-treatment.html">https://www.cancer.org/treatment/survivorship-during-and-after-treatment.html</a>
- MD Anderson Cancer Center Life After Cancer:


https://www.mdanderson.org/patients-family/life-after-cancer.html

#### Clinical Tools and Resources



**Patient Education** 





**Professional Education** 



### Summary

- 1. Long term cancer survivors (5 years or longer) constitute the majority of cancer survivors in the USA today
- 2. More than 2/3 of long term survivors are older adults (65 years and older), and that number will significantly increase over the next 20 years, as predicted by SEER statistics based on the aging US population
- 3. The needs of survivors are driven not only by their age and health conditions, but also by the prior cancer diagnosis and the cancer treatment received
- 4. While breast and prostate cancer survivors constitute nearly half of the total survivor population, the dropping mortality rates in lung and other solid tumors is increasingly diversifying the groups of survivors
- 5. The key components of survivorship care as supported by the 2006 IOM report are intended to address the issues faced by survivors after their treatment ends, and these domains include surveillance, prevention/screening for second primary cancers, management of late effects, and psychosocial health
- 6. The primary care clinical community increasingly will be caring for cancer survivors in their practice, and coordinated information exchange with and from the oncology providers is very important to the seamless transition of the patients' care



### The Challenge of Survivorship

 The challenge in overcoming cancer is not only to find therapies that will prevent or arrest the disease quickly, but also to map the middle ground of survivorship and minimize its medical and social hazards



• Fitzhugh Mullan. Seasons of Survival: Reflections by a Physician with Cancer. NEJM 1985;313(4):270-3.